Name: MarketsandMarkets Biomarker and Companion Diagnostics Conference
Start: 2019-10-03
End: 2019-10-04
Location: Radisson Blu Edwardian, Grafton Hotel, London

5 +

Sessions

20+

Speakers

150 +

Attendees

10+

Networking Hours

EVENT OVERVIEW

Redefining clinical stage biomarker strategies for a successful CDx commercialization

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.

Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.

Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

Clinical Biomarker Identification & Qualification

Biomarker and Personalized Medicine

Commercializing Biomarker in Therapeutic and Companion Diagnostic Applications

Clinical biomarker identification and qualification
Biomarkers and personalized medicine
Assay development and validation
NGS and novel technologies in biomarker discovery
Commercialization of biomarkers in therapeutic and CDx applications

Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairman Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	08:55 - 09:00
Keynote Presentation: Biomarker Immunossays in multiplex and their Application in Preclinical and Clinical Research Thomas Joos, Deputy Managing Director, University of Tübingen	09:00 - 09:30
CLINICAL BIOMARKER IDENTIFICATION & QUALIFICATION
Biosensing and imaging with upconversion nanoparticles Prof. Gin Jose, Chair in Functional Materials, University of Leeds	09:30 - 10:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Illip Burmester, Ph.D. , Scientific Sales Support Europe, Proteome Sciences	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:20
Quantitative Methods towards Actionable Biomarkers Dr. Richardus Vonk, VP, Head Oncology Statistics and Data Management, Bayer AG	11:20 - 11:50
High Definition Multiplexing for Biomarker Strategies and CDx Development Louis Levy, Director of Corporate and Business Development, Ultivue	11:50 - 12:20
Considerations for developing clinical Biomarker strategies in immuno-oncology Stephanie Traub, Associate Director, Translational Biomarkers & Bioanalysis, UCB	12:20 - 12:50
Validation of a digital pathology workflow: a lab experience. Shanon Seger, Scientist - Imaging Specialist, Roche	12:50 - 13:20
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:20 - 14:20
BIOMARKERS & PERSONALIZED MEDICINE
Circulating biomarkers- the bright future in cancer diagnosis and precision medicine Yong-Jie Lu , Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)	14:20 - 14:50
Digital Biomarkers transforming drug development and precision health practices Dan Sikkema, Vice President, Quanterix	14:50 - 15:20
A Novel technique to analyse biomarkers for critical diseases Dr. Sikha Saha, Associate Professor of Cardiovascular and Cerebrovascular Medicine, University of Leeds	15:20 - 15:50
Exosome Based Liquid Biopsies Mikkel Noerholm, VP of Product Development, Exosome Diagnostics	15:50 - 16:20
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	16:20 - 17:10
Imaging Biomarkers of breast cancer risk Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester	17:10 - 17:40
Biomarkers and personalized medicine Dr. Bernadett Szabados, Clinical Research Associate, Barts Cancer Institute	17:40 - 18:10
Closing Remarks from the Chairman	18:10 - 18:15
Drinks Reception & Networking	18:15 - 19:00

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairman Yong-Jie Lu , Professor of Molecular Oncology (Barts Cancer Institute), Queen Mary University of London (QMUL)	08:55 - 09:00
Keynote Presentation: Functional Proteomic Biomarkers Peter Parker, Director of the CRUK KHP Centre and Professor of Cancer Cell Biology, KCL	09:00 - 09:30
COMMERCIALIZING BIOMARKERS IN THERAPEUTIC AND COMPANION DIAGNOSTIC APPLICATIONS
Pathway Biomarkers for Precision Medicine Dr. Paul J. Skipp, Associate Professor/Centre Director, Centre for Proteomic Research, University of Southampton	09:30 - 10:00
Implementing Immunosequencing as New Molecular Biomarkers of Response to Immunotherapy Ned Sherry, Manager, Research and Business Development, Adaptive Biotechnologies	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:20
Precision Medicine in Hematology: Measurable residual disease hope, hype or both? Celine Pallaud, Executive Director, Oncology Precision Medicine Hematology DA Lead, Novartis	11:20 - 11:50
Development of an integrated platform for biomarker and drug target discovery using proteomics Tony Whetton, Professor of Cancer Cell Biology, University of Manchester	11:50 - 12:20
The clinical and regulatory development of a Trastuzumab biosimilar: the story of CT-P6 Justin Stebbing, Professor of Cancer Medicine and Oncology, Imperial College London	12:20 - 12:50
Longitudinal and Network Serum Biomarker Models for Early Detection of Ovarian Cancer John Timms, Reader in Cancer Proteomics, University College London	12:50 - 13:20
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:20 - 14:20
Functional Biomarkers of DNA repair Nicola Curtin, Professor of Experimental Therapeutics, Newcastle University	14:20 - 14:50
Biomarkers for early Pancreatic Cancer detection Eithne Costello-Goldring, Professor of Molecular Oncology, University of Liverpool	14:50 - 15:20
Biomarker commercialization support tool for researchers Valerie Daussin Laurent, , Business Developer, Aalborg University Hospital and Project Leader, BIC Consortium	15:20 - 15:50
Novel serum biomarkers for fatty liver disease Dr. Bevin Gangadharan, Research Associate, University of Oxford	15:50 - 16:20
Closing remarks from the chairman	16:20 - 16:25